Should We Target Obesity in Advanced Heart Failure?

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2014 Feb 1

PMID 24482160

Citations 4

Authors

Amanda R Vest

James B Young

Affiliations

Soon will be listed here.

Abstract

Obesity is a risk factor for the development of heart failure (HF), but has been associated with improved survival in patients with established HF. Weight loss should clearly be recommended and supported for obese individuals without cardiac pathology to prevent cardiomyopathy development. Clinical recommendations at the other end of the obesity heart failure spectrum are also relatively clear. Morbidly obese individuals (BMI ≥ 40 kg/m(2)) aged <50 years with severely depressed systolic function and NYHA class III-IV symptoms should be considered for malabsorptive bariatric surgery at an experienced center. The goal is either improved systolic function and symptoms, or sufficient weight loss for heart transplant eligibility. Recommendations for patients falling between these extremes are more challenging. Overweight and mildly obese HF patients (25-35 kg/m(2)) may be somewhat protected from cardiac cachexia and weight loss is not expected to enhance survival, but may offer symptomatic benefits.

Citing Articles

Is the obesity paradox in outpatients with heart failure reduced ejection fraction real?.

Salvino N, de Sousa L, Abrahao F, Spineti P, Sales A, Neves de Albuquerque F Front Cardiovasc Med. 2023; 10:1239722.

PMID: 38149266 PMC: 10750383. DOI: 10.3389/fcvm.2023.1239722.

Morbid Obesity as a Therapeutic Target for Heart Failure.

Albert C Curr Treat Options Cardiovasc Med. 2019; 21(10):52.

PMID: 31486922 DOI: 10.1007/s11936-019-0754-z.

A Population-Based Study of Early Postoperative Outcomes in Patients with Heart Failure Undergoing Bariatric Surgery.

Strong A, Sharma G, Tu C, Aminian A, Young J, Rodriguez J Obes Surg. 2018; 28(8):2281-2288.

PMID: 29512040 DOI: 10.1007/s11695-018-3174-3.

INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist.

Ramos H, Birkenfeld A, de Bold A Endocr Connect. 2015; 4(3):R25-36.

PMID: 26115665 PMC: 4485177. DOI: 10.1530/EC-15-0018.

References

le Roux C, Patterson M, Vincent R, Hunt C, Ghatei M, Bloom S . Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab. 2004; 90(2):1068-71. DOI: 10.1210/jc.2004-1216. View

Bays H . Adiposopathy is "sick fat" a cardiovascular disease?. J Am Coll Cardiol. 2011; 57(25):2461-73. DOI: 10.1016/j.jacc.2011.02.038. View

Kalupahana N, Massiera F, Quignard-Boulange A, Ailhaud G, Voy B, Wasserman D . Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring). 2011; 20(1):48-56. PMC: 4465436. DOI: 10.1038/oby.2011.299. View

Djousse L, Bartz T, Ix J, Zieman S, Delaney J, Mukamal K . Adiposity and incident heart failure in older adults: the cardiovascular health study. Obesity (Silver Spring). 2011; 20(9):1936-41. PMC: 3429627. DOI: 10.1038/oby.2011.320. View

Kenchaiah S, Pocock S, Wang D, Finn P, Zornoff L, Skali H . Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007; 116(6):627-36. DOI: 10.1161/CIRCULATIONAHA.106.679779. View

Khan R, Kato T, Chokshi A, Chew M, Yu S, Wu C . Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail. 2012; 5(3):340-8. PMC: 3354043. DOI: 10.1161/CIRCHEARTFAILURE.111.964031. View

Hu S, Liu S, Katus H, Luedde M . The value of contrast dobutamine stress echocardiography on detecting coronary artery disease in overweight and obese patients. Can J Cardiol. 2007; 23(11):885-9. PMC: 2651366. DOI: 10.1016/s0828-282x(07)70844-9. View

Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow G, Norris C, McAlister F . Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008; 156(1):13-22. DOI: 10.1016/j.ahj.2008.02.014. View

McManus D, Lyass A, Ingelsson E, Massaro J, Meigs J, Aragam J . Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study. Obesity (Silver Spring). 2011; 20(9):1882-6. PMC: 3716016. DOI: 10.1038/oby.2011.32. View

10.

Vila G, Grimm G, Resl M, Heinisch B, Einwallner E, Esterbauer H . B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes. 2012; 61(10):2592-6. PMC: 3447894. DOI: 10.2337/db11-1466. View

11.

Ukkola O, Santaniemi M . Adiponectin: a link between excess adiposity and associated comorbidities?. J Mol Med (Berl). 2002; 80(11):696-702. DOI: 10.1007/s00109-002-0378-7. View

12.

Luaces M, Cachofeiro V, Garcia-Munoz-Najar A, Medina M, Gonzalez N, Cancer E . Anatomical and functional alterations of the heart in morbid obesity. Changes after bariatric surgery. Rev Esp Cardiol (Engl Ed). 2011; 65(1):14-21. DOI: 10.1016/j.recesp.2011.06.018. View

13.

Kenchaiah S, Sesso H, Gaziano J . Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2008; 119(1):44-52. PMC: 2727738. DOI: 10.1161/CIRCULATIONAHA.108.807289. View

14.

Li X, Li S, Ulusoy E, Chen W, Srinivasan S, Berenson G . Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. Circulation. 2004; 110(22):3488-92. DOI: 10.1161/01.CIR.0000149713.48317.27. View

15.

Flegal K, Carroll M, Ogden C, Curtin L . Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303(3):235-41. DOI: 10.1001/jama.2009.2014. View

16.

Wannamethee S, Shaper A, Whincup P, Lennon L, Sattar N . Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role?. J Am Coll Cardiol. 2011; 58(18):1870-7. DOI: 10.1016/j.jacc.2011.06.057. View

17.

Sokos G, Nikolaidis L, Mankad S, Elahi D, Shannon R . Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12(9):694-9. DOI: 10.1016/j.cardfail.2006.08.211. View

18.

Saltijeral A, de Isla L, Perez-Rodriguez O, Rueda S, Fernandez-Golfin C, Almeria C . Early myocardial deformation changes associated to isolated obesity: a study based on 3D-wall motion tracking analysis. Obesity (Silver Spring). 2011; 19(11):2268-73. DOI: 10.1038/oby.2011.157. View

19.

Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W . Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001; 104(12):1430-5. DOI: 10.1161/hc3601.095575. View

20.

Wang J, Sarnola K, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M . The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Atherosclerosis. 2009; 210(1):237-42. DOI: 10.1016/j.atherosclerosis.2009.10.042. View